The most common treatment-related adverse events of grade @ or worse in the linsitinib group were fatigue ( three -LSB- @ % -RSB- patients vs no patients in the placebo group ) , nausea ( two -LSB- @ % -RSB- vs none ) , and hyperglycaemia ( two -LSB- @ % -RSB- vs none ) .